share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  08/16 16:09
Moomoo AI 已提取核心訊息
On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will...Show More
On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will receive a 3% commission on gross proceeds and will be indemnified by NeuroSense, which will also reimburse certain expenses. The agreement includes customary representations, warranties, and conditions. This report, along with the full text of the Sales Agreement and the legal opinion of Goldfarb Gross Seligman & Co., is incorporated by reference into the company's existing registration statements.
2024年8月16日，外國私人發行人NeuroSense Therapeutics Ltd.宣佈與JonesTrading Institutional Services LLC簽署了一份按需資本銷售協議。根據該協議，NeuroSense可以提供並出售總價值高達2,524,437美元的普通股。這些銷售將通過「市場定價方式」進行，該方式在1933年證券法案規定的415號法規中有所定義，並可能在納斯達克資本市場或其他交易市場上進行銷售。該發行將根據2023年1月向美國證券交易委員會提交的一個貨架註冊聲明和招股說明書進行。NeuroSense沒有義務出售任何股份，該協議可以由任何一方或經雙方協議終止。銷售代理將獲得總收益的3%的佣金，並由NeuroSense對其進行保障，還將報銷某些費用。該協議包括定製的陳述、保證和條件。本報告以及銷售協議的全部文本和Goldfarb Gross Seligman& Co.的法律意見已經獲得了公司現有的註冊聲明的參考。
2024年8月16日，外國私人發行人NeuroSense Therapeutics Ltd.宣佈與JonesTrading Institutional Services LLC簽署了一份按需資本銷售協議。根據該協議，NeuroSense可以提供並出售總價值高達2,524,437美元的普通股。這些銷售將通過「市場定價方式」進行，該方式在1933年證券法案規定的415號法規中有所定義，並可能在納斯達克資本市場或其他交易市場上進行銷售。該發行將根據2023年1月向美國證券交易委員會提交的一個貨架註冊聲明和招股說明書進行。NeuroSense沒有義務出售任何股份，該協議可以由任何一方或經雙方協議終止。銷售代理將獲得總收益的3%的佣金，並由NeuroSense對其進行保障，還將報銷某些費用。該協議包括定製的陳述、保證和條件。本報告以及銷售協議的全部文本和Goldfarb Gross Seligman& Co.的法律意見已經獲得了公司現有的註冊聲明的參考。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息